LivaNova (NASDAQ:LIVN) Releases Earnings Results, Beats Expectations By $0.17 EPS

LivaNova (NASDAQ:LIVN) issued its earnings results on Wednesday. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.09 by $0.17, FiscalAI reports. The business had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. LivaNova had a return on equity of 16.36% and a net margin of 12.82%.LivaNova’s revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.05 earnings per share. LivaNova updated its FY 2026 guidance to 4.300-4.400 EPS.

Here are the key takeaways from LivaNova’s conference call:

• Q2 revenue rose 9.8% on a constant-currency basis to a record $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by growth in Cardiopulmonary and Epilepsy.
• LivaNova raised its 2026 revenue-growth outlook to 8%–9% and adjusted EPS guidance to $4.30–$4.40; Cardiopulmonary and Epilepsy growth expectations were also increased.
• The company is expanding oxygenator capacity through a new production line expected to go live in the second half of 2026 and a long-term Thermo Fisher agreement for a critical component, supporting potential market-share gains.
• Epilepsy momentum benefited from improved reimbursement, clinical evidence, higher realized pricing and a stronger patient funnel; management said new-patient implants are growing in existing accounts and through new account activations.
• Adjusted free-cash-flow guidance was reduced to $140 million–$160 million from $160 million–$180 million as capital spending rises to $135 million, while the OSA PMA supplement submission was pushed to between the second half of 2026 and the first half of 2027.

LivaNova Stock Up 0.6%

Shares of NASDAQ:LIVN traded up $0.44 on Friday, reaching $76.22. The company had a trading volume of 744,982 shares, compared to its average volume of 778,520. The stock has a market capitalization of $4.19 billion, a P/E ratio of 22.55 and a beta of 0.86. The stock has a 50-day moving average price of $79.60 and a 200 day moving average price of $70.71. LivaNova has a twelve month low of $48.57 and a twelve month high of $85.76. The company has a quick ratio of 1.11, a current ratio of 1.45 and a debt-to-equity ratio of 0.22.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LIVN. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Robert W. Baird dropped their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. KeyCorp raised their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Needham & Company LLC lifted their price target on LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Stifel Nicolaus set a $85.00 price target on LivaNova in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $83.50.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Large investors have recently modified their holdings of the company. Empowered Funds LLC bought a new stake in LivaNova during the 4th quarter valued at approximately $107,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of LivaNova during the fourth quarter worth approximately $145,000. iSAM Funds UK Ltd bought a new stake in shares of LivaNova in the third quarter valued at approximately $218,000. Headlands Technologies LLC boosted its position in shares of LivaNova by 270.8% in the second quarter. Headlands Technologies LLC now owns 3,456 shares of the company’s stock valued at $156,000 after acquiring an additional 2,524 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in shares of LivaNova in the second quarter worth $218,000. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.